Endolymphatic therapy for chronic lymphovenous insufficiency complicated by trophic ulcers

This article puts forward a method of endolymphatic administration of immunostimulants, which directly affect the immunocompetent cells in lymph nodes so that their effect is much more pronounced. From this perspective, selenase is especially promising, as it not only shows a pronounced antioxidant effect, but also an immunomodulating effect, which means that it normalizes the status of different parts of the immune system, as well as the immunological tolerance. This enables endolymphatic administration of drug. This article evaluates the treatment of trophic ulcers of the lower extremities in 58 patients. The main group consisted of 30 patients at mean age 68.2 (14 or 46.7%, were men; 16, or 53.3%, were women). The reference group consisted of 28 patients at mean age 67.9 (12 or 43%, were men; 16 or 57%, were women). Trials proved that endolymphatic therapy is a selective targeting on the site of pathology and the main routes of lymphatic drainage. Endolymphatic therapy improves the short-terms and long-term outcomes of patients with trophic ulcers that appeared on the background of lymphovenous problems. Clinical trial has shown that trophic ulcers were healing better in the main group. The best outcomes were displayed by 19 (63.3%) patients from the main group and 13 (46.4%) patients from the reference group. This article reports on originally designed program of complex treatment for patients with trophic ulcers that appeared on the background of lymphovenous insufficiency of the lower extremities, which implies the infusion of meronem, selenase and sulodexide as endolymphatic therapy. Designed program was proved to be effective.